Paper40121031
PLS-α-GalCer: a novel targeted glycolipid therapy for solid tumors.
Burks J and 6 others. J Immunother Cancer, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. PLS-α-GalCer: a novel targeted glycolipid therapy for solid tumors. Papers, record 40121031. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40121031
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Galactosylceramides | Major topic |
| Neoplasms | Major topic |
| Pancreatic Neoplasms | Major topic |
| Glycolipids | Major topic |
| Animals | |
| Mice | |
| Humans | |
| Female | |
| Cell Line, Tumor | |
| Natural Killer T-Cells |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| 75N91019D00024 | NCI NIH HHS | United States | PubMed | PubMed | |
| F22CA000024 | NIH | NIH RePORTER | |||
| ZIASC004020 | NIH | NIH RePORTER | |||
| ZICBC010936 | NIH | NIH RePORTER |
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32841040 | Application of a Scavenger Receptor A1-Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV. | Mol Pharm | 2020 | https://conductscience.org/library/papers/32841040 | PubMed |
| 2 | 15756017 | A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. | Clin Cancer Res | 2005 | https://conductscience.org/library/papers/15756017 | PubMed |
| 3 | 30568305 | Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. | Nature | 2019 | https://conductscience.org/library/papers/30568305 | PubMed |
| 4 | 28860937 | A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies. | Cent Eur J Immunol | 2017 | https://conductscience.org/library/papers/28860937 | PubMed |
| 5 | 10199836 | Distinct scavenger receptor expression and function in the human CD14(+)/CD16(+) monocyte subset. | Am J Physiol | 1999 | https://conductscience.org/library/papers/10199836 | PubMed |
| 6 | 19055947 | The role of NKT cells in tumor immunity. | Adv Cancer Res | 2008 | https://conductscience.org/library/papers/19055947 | PubMed |
| 7 | 24507759 | A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. | J Ovarian Res | 2014 | https://conductscience.org/library/papers/24507759 | PubMed |
| 8 | 16138189 | Activation or anergy: NKT cells are stunned by alpha-galactosylceramide. | J Clin Invest | 2005 | https://conductscience.org/library/papers/16138189 | PubMed |
| 9 | 8866665 | KRN7000, a novel immunomodulator, and its antitumor activities. | Oncol Res | 1995 | https://conductscience.org/library/papers/8866665 | PubMed |
| 10 | 31244823 | α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials. | Front Immunol | 2019 | https://conductscience.org/library/papers/31244823 | PubMed |
| 11 | 12077264 | Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. | J Immunol | 2002 | https://conductscience.org/library/papers/12077264 | PubMed |
| 12 | 24440852 | Tumor-induced perturbations of cytokines and immune cell networks. | Biochim Biophys Acta | 2014 | https://conductscience.org/library/papers/24440852 | PubMed |
| 13 | 21675859 | Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro. | Nanomedicine (Lond) | 2011 | https://conductscience.org/library/papers/21675859 | PubMed |
| 14 | 32833941 | T-Cell Immunity in Pancreatic Cancer. | Pancreas | 2020 | https://conductscience.org/library/papers/32833941 | PubMed |
| 15 | 28678778 | An immunogenic personal neoantigen vaccine for patients with melanoma. | Nature | 2017 | https://conductscience.org/library/papers/28678778 | PubMed |
| 16 | 11101862 | NKT cells and tumor immunity--a double-edged sword. | Nat Immunol | 2000 | https://conductscience.org/library/papers/11101862 | PubMed |
| 17 | 33969083 | Immunotherapy for pancreatic cancer. | World J Clin Cases | 2021 | https://conductscience.org/library/papers/33969083 | PubMed |
| 18 | 23064364 | Scavenger receptors target glycolipids for natural killer T cell activation. | J Clin Invest | 2012 | https://conductscience.org/library/papers/23064364 | PubMed |
| 19 | 34465781 | A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity. | Nat Commun | 2021 | https://conductscience.org/library/papers/34465781 | PubMed |
| 20 | 32328176 | DNT Cell-based Immunotherapy: Progress and Applications. | J Cancer | 2020 | https://conductscience.org/library/papers/32328176 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42894632 | Poloxamer-Based Th1-Biased NKT Cell Nano-Agonist for Tumor Immunotherapy. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42894632 | PubMed |
| 42819957 | All-Hydrocarbon Macrocycle Enables Highly Potent Th1-Biased NKT Cell Agonists for Immunotherapy. | JACS Au | 2026 | https://conductscience.org/library/papers/42819957 | PubMed |
| 41755879 | Highly Potent Th1-Type NKT Cell Agonists as Immunotherapeutic Agents via Conformational Restriction Design. | JACS Au | 2026 | https://conductscience.org/library/papers/41755879 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40121031
GET https://conductscience.org/api/papers/v1/40121031/references?page=2